Diniz-Freitas M, Fernández-Feijoo J, Fernández-Montenegro P, González-Mosquera A, Vázquez-García E, Diz-Dios P. Criteria for the prescription of oral bisphosphonates for the treatment of osteoporosis in a series of women referred for tooth extraction. Med Oral Patol Oral Cir Bucal. 2012 Jul 1;17 (4):e601-4.

doi:10.4317/medoral.17681

http://dx.doi.org/doi:10.4317/medoral.17681

1. Grupo de trabajo de la Sociedad Española de Investigaciones Óseas y Metabolismo mineral. Postmenopausal osteoporosis. Clinical practice guide. Rev Clin Esp. 2003;203:496-506.
PMid:14563246

2. Erviti J. Drugs prescription for osteoporosis. An Sist Sanit Navar. 2003;26:107-21.
PMid:14716363

3. Chapurlat RD, Delmas PD. Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006;2:211-9.
http://dx.doi.org/10.1038/ncpendmet0121
PMid:17082810

4. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the Jaws-2009 update. J Oral Maxillofac Surg. 2009;67:2-12.
http://dx.doi.org/10.1016/j.joms.2009.01.009
PMid:19371809

5. Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST, Kolk A, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence -a multi-centre study. J Craniomaxillofac Surg. 2011;39:272-7.
http://dx.doi.org/10.1016/j.jcms.2010.05.009
PMid:20580566

6. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007;18:1363-70.
http://dx.doi.org/10.1007/s00198-007-0384-2
PMid:17598065

7. Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19-26.
http://dx.doi.org/10.1111/j.1742-1241.2008.01911.x
PMid:19125989    PMCid:2705815

8. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rept Ser. 1994;843:1-129.
PMid:7941614

9. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006;119:S3-S11.
http://dx.doi.org/10.1016/j.amjmed.2005.12.017
PMid:16563939

10. de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T. Clinical characteristics of patients under treatment for osteoporosis in a Primary Care Centre. Who do we treat? Aten Primaria. 2010;42: 559-63.
http://dx.doi.org/10.1016/j.aprim.2009.10.022
PMid:20129712

11. McLeod KM, Johnson CS. Identifying women with low bone mass: A systematic review of screening tools. Geriatr Nurs. 2010;30:164-73.
http://dx.doi.org/10.1016/j.gerinurse.2008.07.003
PMid:19520227

12. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
http://dx.doi.org/10.1016/j.joms.2007.08.003
PMid:18022461

13. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009;24:561-74.
http://dx.doi.org/10.1359/jbmr.090203
PMid:19257812

14. Cardona F, Bagán JV, Sáinz E, Figuerido J, Giner F, Vidán FJ. [Bisphosphonate-related osteonecrosis of the jaws. An update]. An Sist Sanit Navar. 2009;32:413-21.
http://dx.doi.org/10.4321/S1137-66272009000500012
PMid:20094102

15. Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg. 2010;68:2241-7.
http://dx.doi.org/10.1016/j.joms.2010.05.043
PMid:20728033